ArticleFrontiers in microbiology2021
Heteroresistance to Amikacin in Carbapenem-Resistant
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Heteroresistance to amikacin inMicrobiology spectrum · 2026Article
- Genotype-Phenotype Links Between Aminoglycoside-Modifying Enzymes and Aminoglycoside MICs in Aminoglycoside-ResistantMicroorganisms · 2026Article
- Multidimensional characterization of a novel porcine Klebsiella pneumoniae phage Pkp-1.BMC microbiology · 2026Article
- Article
- Detection and characterization of heteroresistance to chloramphenicol in Klebsiella pneumoniae isolates.BMC microbiology · 2025Article
- Emergence of population heterogeneity in Klebsiella pneumoniae with a blaJournal of biomedical science · 2025Article
- Challenges and opportunities of phage therapy forApplied and environmental microbiology · 2024Review
- Emergence of heteroresistance to carbapenems in Gram-negative clinical isolates from two Egyptian hospitals.BMC microbiology · 2024Article
- Article
- Overexpression of KPC contributes to ceftazidime-avibactam heteroresistance in clinical isolates of carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Article
- Detection and characterization of eravacycline heteroresistance in clinical bacterial isolates.Frontiers in microbiology · 2024Article
- Isolation and Characterization of vB_kpnM_17-11, a Novel Phage Efficient Against Carbapenem-ResistantFrontiers in cellular and infection microbiology · 2022Article
- Relationships between Efflux Pumps and Emergence of Heteroresistance: A Comprehensive Study on the Current Findings.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Review
- Antibiotic Heteroresistance inInternational journal of molecular sciences · 2021Review
- In Vitro Synergism of Azithromycin Combination with Antibiotics against OXA-48-ProducingAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heteroresistance can lead to treatment failure and is difficult to detect by the methods currently employed by clinical laboratories. The aim of this study was to investigate the prevalence of the amikacin-heteroresistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.